All In Biotech

Drug Trial Radar · NCT01998984

Efficacy and Safety of Ingenol Mebutate Gel 0.06% When Applied Once Daily for 2, 3 or 4 Consecutive Days to a Treatment Area of Approximately 250 cm2 on Trunk and Extremities in Subjects With Actinic Keratosis

Last checked: Nov 20, 2026Latest source record: Mar 10, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 266 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

266

Actual

Start

Jan 2014

Primary completion

Jul 2014

Study completion Jul 2014

Sponsor

Lead sponsor
LEO PharmaIndustry
Sponsor type
Industry
First posted
Dec 3, 2013

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a randomised, double-blind, parallel groups, vehicle controlled, 8-week phase 2 trial. The objective is to evaluate efficacy of ingenol mebutate gel 0.06 % after once daily treatment for 2, 3 or 4 consecutive days compared to vehicle gel

Conditions

  • Actinic Keratosis

Interventions

  • ingenol mebutateDrug

  • PlaceboOther

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants With Complete Clearance of Actinic Keratosis Lesions (AKs)Time frame: At Week 8

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Long Island Skin Cancer and Dermatologic Surgery

    Smithtown, New York

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.